Compare Inovio Pharmaceuticals Inc (INO) vs Sea Limited (SE) Price & Performance

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.

Sea Limited (SE) trades at $106.00, up 1.87% on the day, with a bearish technical signal despite bullish moving averages. The company reported strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarterly earnings have been mixed. Positive cash flow trends and a robust analyst consensus with a $131.00 price target highlight fundamental strength, but insider selling and competitive pressures present headwinds.

The outlook for SE is cautiously optimistic, driven by sustained revenue expansion and improving profitability. Key risks include execution challenges in its e-commerce and gaming segments, geopolitical tensions affecting operations, and insider selling activity. The stock's valuation multiples suggest growth expectations are priced in, requiring continued strong performance to justify further upside.